Genetic insight into Birt–Hogg–Dubé syndrome in Indian patients reveals novel mutations at \textit{FLCN}

Anindita Ray$^1$, Esita Chattopadhyay$^{1,6}$, Richa Singh$^{1,7}$, Saurabh Ghosh$^1$, Arnab Bera$^{2,3}$, Mridul Sarma$^{4,5}$, Mahavir Munot$^6$, Unnati Desai$^6$, Srijeet Rajan$^7$, Pralhad Prabhudesai$^8$, Ashish K. Prakash$^9$, Sushmita Roy Chowdhury$^{10,11}$, Niladri Bhowmick$^{12}$, Raja Dhar$^{13}$, Zarir F. Udwadia$^{14}$, Atin Dey$^2$, Subhra Mitra$^4$, Jyotsna M. Joshi$^6$, Arindam Maitra$^{15}$ and Bidyut Roy$^{1*}$

Abstract

\textbf{Background:} Birt-Hogg-Dubé syndrome (BHDS) is a rare monogenic condition mostly associated with germline mutations at \textit{FLCN}. It is characterized by either one or more manifestations of primary spontaneous pneumothorax (PSP), skin fibrofolliculomas and renal carcinoma (chromophobe). Here, we comprehensively studied the mutational background of 31 clinically diagnosed BHDS patients and their 74 asymptomatic related members from 15 Indian families.

\textbf{Results:} Targeted amplicon next-generation sequencing (NGS) and Sanger sequencing of \textit{FLCN} in patients and asymptomatic members revealed a total of 76 variants. Among these variants, six different types of pathogenic \textit{FLCN} mutations were detected in 26 patients and some asymptomatic family members. Two of the variants were novel mutations: an 11-nucleotide deletion (\textit{c.1150\_1160delGTC CAG TCAGC}) and a splice acceptor mutation (\textit{c.1301-1G > A}). Two variants were Clinvar reported pathogenic mutations: a stop-gain (\textit{c.634C > T}) and a 4-nucleotide duplication (\textit{c.1329\_1332dupAGCC}). Two known variants were: hotspot deletion (\textit{c.1285delC}) and a splice donor mutation (\textit{c.1300+1G > A}). \textit{FLCN} mutations could not be detected in patients and asymptomatic members from 5 families. All these mutations greatly affected the protein stability and \textit{FLCN-FNIP2} interaction as observed by molecular docking method. Family-based association study inferred pathogenic \textit{FLCN} mutations are significantly associated with BHDS.

\textbf{Conclusion:} Six pathogenic \textit{FLCN} mutations were detected in patients from 10 families out of 15 families in the cohort. Therefore, genetic screening is necessary to validate the clinical diagnosis. The pathogenic mutations at \textit{FLCN} affects the protein–protein interaction, which plays key roles in various metabolic pathways. Since, pathogenic mutations could not be detected in exonic regions of \textit{FLCN} in 5 families, whole genome sequencing is necessary to detect all mutations at \textit{FLCN} and/or any undescribed gene/s that may also be implicated in BHDS.

\textbf{Keywords:} \textit{FLCN} mutations, BHDS, Primary spontaneous pneumothorax, Family-based association, Molecular docking, Indian patients

\*Correspondence:  bidyutroy8933@gmail.com; broy@isical.ac.in

1 Human Genetics Unit, Indian Statistical Institute, Kolkata, India

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spontaneous pneumothorax (PSP; [MIM: 173600]) and/or lung cysts, and chromophobe or oncocyctic renal cell carcinoma are two other manifestations in BHDS [2, 3]. It follows autosomal dominant pattern of inheritance with incomplete penetrance [4] and is known to be monogenic, associated with germ line mutations at Folliculin (FLCN; NM_144997.5) located at 17p11.2 [5]. More than 290 pathogenic germ line mutations at FLCN have been reported in BHDS [6]. Among these, a hotspot protein truncating mutation in a hypervariable poly-C tract (C<sub>8</sub>) in exon 11 (c.I285) has been reported in different populations [7, 8]. BHDS chromophobe renal tumours exhibit loss of heterozygosity (LOH), suggesting a tumour suppression role of FLCN in kidney [9]. Haploinsufficiency at FLCN has also been reported in BHDS manifestations [10, 11]. FLCN protein is similar to DENN domain proteins, though its exact function is unknown [12]. It interacts via its carboxy-terminal (C-terminal) with two proteins—Folliculin interacting protein 1 and 2 (FNIP1 and FNIP2) [5]. These complexes play important roles in major metabolic pathways such as modulation of mTOR pathway [13], AMPK activation [14, 15], PGC1-α regulation, mitochondrial biogenesis [16], GAP dependant mTORC1 activation [17], HIFα transcription [18], cell-cell adhesion [19], membrane trafficking [20], autophagy [21], ciliogenesis [22], and cell cycle progression [23].

Skin fibrofolliculomas and pathogenic FLCN mutations are two major diagnostic criteria for BHDS, while lung and kidney phenotypes, and presence of first degree family history are known to be minor criteria [24]. However, these manifestations could be population-specific, as skin fibrofolliculomas are not prevalent in East Asian cohorts [25]. A few other similar conditions like Homocystinuria, alpha-1 antitrypsin deficiency, vascular Ehlers-Danlos syndrome, Lymphangioleiomyomatosis (LAMS) may have overlapping pulmonary phenotypes like BHDS, thus confounding disease diagnosis [26].

Studies of more than 600 BHDS families have been reported world-wide with majority of them from the USA and Europe, fewer from Asia (mostly from East Asia) with only one from India [27]. Here, we have comprehensively profiled germ line mutations in BHDS patients and related family members from 15 Indian families and predicted molecular mechanisms for disease phenotype.

**Clinical characterization of study population**

Patient IDs were assigned anonymously for families, patients and asymptomatic members. We enrolled 31 clinically diagnosed BHDS patients, during 2015–2019, with PSP or BHDS-specific lung cysts along with skin and/or renal manifestations, with/without a positive family history and their 74 asymptomatic family members (Additional file 1: Table S1). Recruitment was done with the help of clinicians from different hospitals in India. Clinical phenotype of each patient was also determined using human phenotype ontology terms (HPO), a web-based tool, Phenomizer [28, 29]. It evaluates patient-specific HPO terms and assigns a p-value to the suspected disease of the patient, based on their ranks through Benjamini–Hochberg multiple correction test.

**Detection of inherited variants at FLCN by different sequencing methods**

*Targeted amplicon next-generation sequencing (NGS)*

Initially, genomic DNA from blood of 20 patients and 15 related asymptomatic members from 11 families were isolated for targeted amplicon NGS (Additional file 1: Table S2). Patient F1-1 was included as a positive control, as mutation at FLCN was previously determined by us [27]. All patients and related asymptomatic family-members were not included for NGS study to minimize sequencing manual errors and logistic problems. The 24 kb FLCN, including UTRs, exons and flanking introns (Additional file 1: Table S3a) was amplified by long PCR. Exon 6 and its flanking 2.8 kb intronic region could not be amplified due to technical limitations but were studied by Sanger sequencing method. Targeted amplicon generation and equimolar pooling were performed (Additional file 2: Methods) before library preparation, which was done using Nextera XT Library Preparation kit (Illumina Inc.). Paired-end 100 bp sequencing was performed in Illumina HiSeq 2500 platform. Adaptor trimmed sequence reads were mapped to the human reference genome build (hg38) using BWA-mem. Standard pipelines were followed for quality filtering and metrics assessment. Germline mutations were called by three variant callers such as Haplotype Caller, STRELKA, VarScan2 (Additional file 2: Methods) [30–36].

**Validation of pathogenic variants and detection of inherited variants in remaining samples**

Bidirectional Sanger sequencing of all exons (Additional file 1: Table S3b) was performed for members of 4 more families; F12, F13, F14 and F15 (9 patients and 20 asymptomatic family members) to detect FLCN mutations. Pathogenic variants (discovered from NGS) were also
validated in all individuals from 11 families (Additional file: Table S2). BioEdit and in-silico tools were used for sequence alignment and variant analysis [37, 38].

**e-QTL analysis for expression and population frequencies of FLCN variants**

Effect of non-coding germline variants on FLCN expression (if any) were examined using computed expression quantitative trait loci (e-QTL) data from GTEx [39]. Since BHDS is a rare disease, population-specific alternate allele frequencies of the non-coding variants were checked in South Asian/Indian population (gnomAD, GenomeAsia100K database) [40, 41].

**Pedigree disequilibrium test (PDT) for association study**

Pathogenic variants and regulatory SNPs at FLCN were tested for association with BHDS in families by PDT. It is based on a test statistic, $T$, which, for a one-tailed test with 5% significance, is considered as significant if values of $T \geq 1.64$ (Additional file 2: Methods) [42].

**Homology modelling and molecular docking**

The cryo-EM structure of FLCN-FNIP2-Rag-Ragulator complex (pdb code: 6ulg) was taken as template for modelling wild-type (wt)/mutant FLCN, wt-FNIP2, wt-Ras-related GTP-binding protein A and protein C (RRAGA and RRAGC) monomers using SWISS-MODEL web server. (Additional file 2: Methods). Monomer-models were visualized at Pymol and validated with PROCHECK [43]. Two sets of molecular docking were performed for wild-type and four mutant monomers of FLCN, each with (i) wt-FNIP2, wt-RRAGA, wt-RRAGC together (4-protein complex), and (ii) wt-FNIP2 (2-protein complex). HADDOCK 2.4 web server Guru Interface was used for macromolecular docking with default parameters for running the program and subsequent analysis (Additional file 2: Methods) [44].

**Copy number variation of FLCN**

Read count normalization of FLCN amplicons generated by NGS of 35 samples was performed by Seqmonk (Additional file 2: Methods) to get an initial indication of any FLCN copy number difference between patients and asymptomatic members in different families. Subsequently, to validate NGS copy number variation data, Taqman copy number assay was performed in 4 families—F3, F4, F9, F15 (Additional file 1: Table S4) and 23 unrelated healthy controls (data not shown). Taqman copy number assays for exon 4 (Hs01200751_cn), exon 8 (Hs01889931_cn), exon 13 (Hs01203178_cn) of FLCN and RNase P (as reference) were performed in real-time PCR instrument. Ct values of FLCN and RNase P were used to determine copy numbers of FLCN (Additional file 2: Methods) following statistical analyses in SPSS.

**Results**

**Demography and clinical manifestations**

Thirty out of 31 clinically diagnosed BHDS patients presented BHDS lung phenotype, with 10 patients also manifesting skin fibrofolliculomas, with/without a positive family history. Patient, F7-49, only presented skin fibrofolliculomas. Three patients also presented chromophobe renal cancer (Additional file 1: Table S5). The male to female ratio was 58% and 41.9% in patients and asymptomatic members, respectively. Age ranged from 18 to 87 years in patients and 7 to 88 years in asymptomatic members. The number of smokers were observed to be more prevalent in patients than asymptomatic members (Table 1).

**Clinical characterization of patients**

Clinical histories of the patients were examined by clinicians from different hospitals. Phenotype ontology analysis revealed 17 HPO terms using Phenomizer (Additional file 3: Figure S1), which assigned PSP and BHDS to 23 of 31 patients, with significant p-values of $\leq 0.05$ (Additional file 1: Table S6 and Additional file 3: Fig. S2). Patient ontology for three patients of family F9 did not qualify for PSP or BHDS. Inconclusive results were obtained for patients, F5–26 and F5–28 (family F5), and F15-99 (family F15), however index patients of both families were significantly assigned with PSP.

**Germline mutations at FLCN**

An average of 7 million reads per sample were obtained from targeted amplicon NGS data (Additional file 1: Table S7), and after various quality filters, it revealed a total of 412 variants (Additional file 3: Fig. S3). Variants from homo-polymeric regions (> 9) were removed to obtain a total of 76 variants. Among these variants; 4 exonic and 2 splice region mutations were found to be pathogenic. Sanger sequencing of FLCN exons validated these 6 pathogenic mutations detected in NGS with 100% concordance (Additional file 3: Figs. S4–1, S4–2, S4–3, S4–4, S4–5 and S4–6). Pathogenic FLCN mutations were detected in 10 out of 15 families recruited in the study. These pathogenic variants were found in 19 of 31 patients and 16 of 74 related asymptomatic members in 10 families (Fig. 1 and Table 2). All 19 patients with pathogenic FLCN mutations presented PSP and/or BHDS lung cysts. Patient F14-95 harboured all three BHDS manifestations (PSP, skin fibrofolliculomas and renal cysts). Two more patients (F3–13, F12-77) had skin fibrofolliculomas, and patient F13-82 had chromophobe renal cell carcinoma. Remaining 70 variants were found in UTRs and introns.
Table 1  Demography and clinical manifestations of patients (n = 31) and asymptomatic members (n = 74)

| Patients (n = 31) | Demography |
|------------------|------------|
| Mean age ± SD (range in years) | 49 ± 15.4, (18–87) |
| Males | 58% (n = 18) |
| Females | 41.9% (n = 13) |
| Smoking habit (> 10 years) | 22% (n = 7) |
| History of tuberculosis | 16% (n = 5) |
| BHDS diagnostic criteria | Number of patients* |
| Patients with lung cysts or PSP | 96% (n = 30) |
| Patients with skin fibrofolliculomas | 35% (n = 11) |
| Patients with renal cysts/carcinoma (chromophobe) | 9.6% (n = 3) |
| Patients having 1st degree relative with similar respiratory phenotype | 64% (n = 20) |

| Asymptomatic family members | n = 74 |
|-----------------------------|-------|
| Mean age ± SD (range in years) | 36 ± 19.8 (7–88) |
| Males | 58% (n = 43) |
| Females | 41.8% (n = 31) |
| Smoking habit (> 10 years) | 1.3% (n = 1) |
| History of tuberculosis | 6.75% (n = 5) |
| BHDS diagnostic criterion (except respiratory or dermal manifestation) | |
| Asymptomatics with renal cysts/carcinoma** | 2.7% (n = 2) |

* Some of the patients had more than one phenotype

** Two individuals from family F7 only presented renal cell carcinoma, but were not clinically evaluated as BHDS. They were third degree relatives of the index patient, therefore they were considered as asymptomatic related members of the index patient

Fig. 1  Pathogenic mutations at FLCN found in patients and asymptomatic members along with their phenotypes. Light blue boxes represent exons and green boxes are exons with pathogenic mutations in FLCN. Most pathogenic mutations were found between exons 10–13. Circles indicate females, squares males. Family numbers are denoted in grey boxes with patients and asymptomatic members harboring pathogenic FLCN mutations. Patient phenotypes are also indicated in red, blue and green colors in individual symbols, and asymptomatic carriers are denoted with a pink dot.
| COORD        | SNP ID          | HGVS          | Consequence     | Exon | Annotation | Ref | Alt | Patients | Asymptomatic members | Reports          |
|--------------|-----------------|---------------|-----------------|------|------------|-----|-----|----------|---------------------|-----------------|
| 17,222,646   | rs558699420     | c.634C>T      | p.Gln212Ter     | 7    |            | C   | T   | F5–25, F5–26, F5–27 | F5–24, F5–32    | Clinvar pathogenic |
| 17,217,085–  | −               | c.1150_1160delGTC | p.Val384Phefs  | 10   |            | CAGTCAGGC |       | F11–70 | F11–73, F11–74    | Novel            |
| 17,217,095   | −               | c.1150_1160delGTC | p.Val384Phefs  | 10   |            | CAGTCAGGC |       | F11–70 | F11–73, F11–74    | Novel            |
| 17,216,395   | rs80388682      | c.1285delIC   | p.His429Thrfs  | 11   |            | C   | C/− | F1–1, F1–2, F12–77 | F1–4 to F1–7, F12–80, F13–89, F15–105, F15–106 | Reported (hotspot) |
| 17,215,284   | −               | c.1329_1332dupAGCC | p.Ala445Serfs  | 12   |            | AGCC | −/AGCC | F4–18 | None               | Clinvar pathogenic |
| 17,216,379   | rs79255676      | c.1300+1G>A   | Splice donor    | 11–12|            | C   | T   | F2–9    | F2–10, F2–12       | Reported         |
| 17,215,317   | −               | c.1301–1G>A*  | Splice acceptor | 11–12|            | C   | T   | F3–13, F3–14 | F3–16, F3–17       | Novel            |

* Novel mutations

COORD Genomic coordinates, Ref reference allele, Alt alternate allele
Table 3  Twelve SNPs with median FLCN expression values in Lung and Skin (exposed) from GTex, and their alternate allele frequencies

| SL No. | SNPs | COORD | SNP ID | Annotation | Ref allele (South Asian/Asian) | Lung (median values of gene expression) | Skin-exposed (median values of gene expression) |
|--------|------|-------|--------|------------|-------------------------------|------------------------------------------|-----------------------------------------------|
|        |      |       |        |            | Ref allele: Reference allele, ALT allele: Alternate allele genotype | REF HET ALT p-value | REF HET ALT p-value |
| SNP 1  | 17,236,986 | rs41345949 | 5′ UTR | C          | T = 0.03/0.05                 | - 0.06 (440) 0.27 (69) N.A 1.10E−07 | - - - - |
| SNP 2  | 17,212,319 | rs7218992 | 3′ UTR | C          | A = −/0.06                   | 0.126 (384) − 0.37 (119) − 0.91 (12) 8.90E−14 | - 0.05 (456) − 0.22 (137) − 0.500 (12) 4.30E−07 |
| SNP 3  | 17,213,262 | rs12602675 | 5′ UTR | C          | T = 0.08/0.08                 | 0.014 (478) − 0.29 (37) N.A 0.0001 | 0.2 (564) − 0.52 (40) N.A 1.10E−09 |
| SNP 4  | 17,221,501 | rs3744124 | Intronic | C          | T = 0.11/0.12                 | 0.07 (452) − 0.44 (62) N.A 2.40E−09 | 0.06 (529) − 0.44 (76) N.A 3.40E−18 |
| SNP 5  | 17,226,931 | rs6502565 | Intronic | C          | T = 0.12/0.13                 | 0.068 (451) − 0.44 (62) N.A 1.80E−09 | 0.06 (528) − 0.46 (76) N.A 1.30E−17 |
| SNP 6  | 17,226,956 | rs76319098 | Intronic | C          | T = 0.12/0.13                 | 0.05 (466) − 0.47 (47) N.A 1.80E−09 | 0.05 (548) − 0.55 (56) N.A 1.20E−17 |
| SNP 7  | 17,228,852 | rs79717038 | Intronic | G          | A = 0.12/0.13                 | 0.06 (464) − 0.47 (49) N.A 2.70E−08 | 0.06 (543) − 0.58 (61) N.A 3.10E−19 |
| SNP 8  | 17,214,314 | rs8067893 | Intronic | G          | A = −/0.11                    | 0.134 (340) − 0.255 (151) − 0.52 (24) 2.80E−12 | 0.08 (407) − 0.23 (168) 0.03 (30) 1.70E−07 |
| SNP 9  | 17,220,853 | rs41323249 | Intronic | C          | T = 0.09/0.11                 | 0.14 (359) − 0.34 (139) − 0.50 (17) 2.60E−14 | 0.07 (430) − 0.12 (153) − 0.73 (22) 4.40E−08 |

COORD: Chromosomal co-ordinates, In expression columns (REF: Homozygous reference genotype, HET: Heterozygote genotype, ALT: Alternate allele genotype), REF allele: Reference allele, ALT allele: Alternate allele frequency in Indian (GenomeAsia100K) and South Asian (gnomAD) population, N.A: Gene expression value not available due to none/very low sample size with particular genotype. The numbers in brackets indicate the number of samples harbouring that genotype.
of FLCN (Additional file 1: Tables S8a and S8b) and among these; 13 and 12 variants were reported as Clinvar 'benign' and non-pathogenic, respectively. Among the 6 pathogenic variants (Fig. 1), two were heterozygous novel mutations: a frame-shift deletion of 11 nucleotides, c.1150_1160delGTCAGTGTCAGC (c.1150_1160del11) in exon 10 in family F11, and a splice acceptor mutation, c.1301-1G>A in intron–exon boundary of exon 12 in family F3. A stop-gain mutation, c.634C>T in exon 7, and a frame-shift duplication of 4 nucleotides, c.1329_1332dupAGCC in exon 12, were found in family F5 and F4, respectively, which were Clinvar reported 'pathogenic' heterozygous mutation. The hotspot heterozygous deletion mutation, c.1285delC in exon 11 was found in 5 families (F1, F12, F13, F14, F15). A reported heterozygous splice donor mutation, c.1300+1G>A was found in exon–intron boundaries of exon 12 in family F2 (Additional file 3: Figs. S4-1, S4-2, S4-3, S4-4, S4-5 and S4-6).

Expression of FLCN: e-QTL study from GTex database

Low FLCN expression is reported in tissues (especially in kidney) of BHDS patients [39, 45]. Therefore, we checked whether non-coding variants also affect FLCN expression. We detected 70 non-coding variants and found 12 SNPs (Table 3) common with e-QTL data of FLCN expression (for lung and skin tissues—Additional file 1: Table S9a), with alternate allele frequencies ≤15% in South Asian population (Additional file 1: Table S9b). These SNPs may affect FLCN expression and among these, alternate allele genotypes (CT/TT & AG/GG) of two SNPs: rs41345949 (C>T) and rs41525346 (A>G), were found to be more frequent in patients compared to asymptomatic family members. The rs41345949, although Clinvar benign, is a highly conserved regulatory SNP with an alternate allele frequency of <3% in Indian population. Interestingly, the TT and/or CT genotypes were found in patients of families without any FLCN pathogenic mutations (families F6 and F7). They were also found in patients, F15-99 and F15-101 (genotype TT), who also harbour c.1285delC FLCN mutation, and patient F4-18 (genotype CT), also harboring c.1329_1332dupAGCC mutation. The rs41525346 is an intronic SNP, highly conserved, and has a distal enhancer-like signature, with an alternate allele frequency of <4% in Indian population.

PDT for family based test of association between FLCN mutations and BHDS

Although c.1285delC mutation is mostly observed in BHDS patients, but other less frequent mutations are also detected in different populations. Considering availability of family data, it is always better to do family based association study rather than case–control study, since family based study is more powerful. To consider less frequent FLCN mutations in patient population, we have performed family based association study including all pathogenic mutations. Five exonic pathogenic FLCN mutations (c.634C>T, c.1150_1160del11, c.1285delC, c.1329_1332dupAGCC, c.1300+1G>A) were tested for family-based association studies. Families F3 and F14 (with c.1301-1G>A and c.1285delC mutations, respectively) were not taken as they lacked the required conditions for the test. Calculating Di for the 8 families (Additional file 1: Table S10a), the test statistic (T) was found to be 1.83 (≥1.64 for significant association). Therefore, the pathogenic FLCN variants are significantly associated with BHDS.

Regulatory SNPs

Apart from regulatory SNP rs41345949 observed in eQTL analysis, we also observed another FLCN SNP, rs1708629, affecting FLCN expression and disease penetrance [46]. TDT was also performed for these two SNPs for all families (Additional file 1: Tables S10b and S10c). Calculating for Di, where i = 1 to 6 (6 families) and i = 1 to 5 (5 families) for rs1708629 and rs41345949, respectively; the test statistic (T) was found to be 0.93 for rs1708629 and 0.85 for rs41345949. Therefore, these SNPs were not significantly associated with the BHDS.

Mutational effects on FLCN: in silico study

FLCN protein has two distinct terminals: Longin/N-terminal (Lys105—Cys265) and C-terminal (Pro344—Met566) (Additional file 3: Fig. S5a). Three of four frame-shift (fs), protein-truncating mutations mapped to the C-terminal: p.Val384Phe*2, p.His429Thr*39, p.Ala445Ser*11, while, p.Gln212Ter mapped to N-terminal (Additional file 3: Fig. S5b) region. All four exonic mutations have pathogenic CADD scores (>15) and resulted in a premature truncation of the protein (Fig. 2 and Additional file 1: Table S11). MaxEnt scores were 8.18 and 8.75 for the splice donor (c.1300+1G>A) and splice acceptor (c.1301-1G>A) mutations, and both had pathogenic CADD scores (34 and 33, respectively).

Homology modelling of wild-type/mutant FLCN and effect on protein–protein interaction

Homology modeled complex of wild type (wt) or four mutant FLCN (p.Q212*, p.V384F*2, p.H429T*39, p.A445S*11), with wt-FNIP2, wt-RRAGA, and wt-RRAGC were validated by PROCHECK, with more than 98% residues in the allowed region of the Ramachandran plot (Additional file 1: Table S12), thus these monomers were accepted for further analyses. Macromolecular docking revealed HADDOCK scores of −342.2±0.0 and −53.1±0.3 for wt-FLCN-FNIP2-RRAGA-RRAGC.
and wt-FLCN-FNIP2 respectively. These data suggested the native FLCN-FNIP2 complex has weaker stability than the wild type four proteins complex. Each of four FLCN mutant monomers was docked with either wt-FNIP2-RRAGA-RRAGC or wt-FNIP2 and it resulted in lesser negative HADDOCK scores and low buried surface areas (BSA) than their native complexes (Additional file 1: Tables S13a and S13b). Less negative HADDOCK scores indicate a lower affinity between interacting partners, and low BSA indicates weaker protein stability. The HADDOCK score of exon-7 mutant-FLCN (p. Q212*) docked with wt-FNIP2-RRAGA-RRAGC had the least negative score (203.2 ± 30.5) than the other three mutant FLCN complexes (−252.1 ± 20.6, −264.6 ± 18.1, −242.8 ± 2.8). On the other hand, in two protein docking complex, exon-10 mutant-FLCN (p. V384F*2) had least negative HADDOCK score (−32.0 ± 19.4) followed by exon-11, exon-12 and exon-7 mutant FLCN (−37.6 ± 11.5, −40.2 ± 7.4, and 47.9 ± 11.9, respectively). So, there was a considerable loss of interaction in all mutant complexes (Additional file 3: Figs. S6a and S6b).

Copy number evaluation of FLCN by Taqman assays
NGS data of FLCN revealed a difference in log transformed normalized read counts between patients and asymptomatic members particularly in four families (F3, F4, F9 and F10) (Additional file 3: Fig. S7). To validate these differences in normalized read counts, Taqman copy number assay was performed. Ct values were obtained from Taqman assays for exons 4, 8 and 13 of FLCN, for all members of the four families and 23 unrelated healthy controls. Normalized Ct values for the exons (dCT or ΔCt) were obtained and transformed to $2^{-\Delta\text{Ct}}$ for further analysis (Fig. 3). Analysis revealed a significant copy number difference for exon 8 in both patients and asymptomatic members compared to unrelated controls (p-values 0.019 and 0.008, respectively), but not between patients and asymptomatic members in any of the three exon assays (exon 4, 8 and 13). But non-parametric test for exon 4 assay and parametric unpaired t-test for exon 13 assay, in patients and asymptomatic members in comparison to unrelated controls did not result any significant copy number difference (Additional file 1: Table S14).

For better understanding of sample sizes used in different experiments and results; a summary flow chart (Additional file 4: Summary of the study) is added.

Discussion
In this study, BHDS lung phenotype (PSP and/or multiple bilateral lung cysts) was found to be most prevalent followed by skin fibrofolliculomas and renal cysts/carcinoma (chromophobe) (Table 1). This observation is in accordance with several East Asian studies, where the lung phenotype is more common (87.3%), than skin lesions (36.7%) and kidney cancer (7.2%), unlike studies from Western countries [25]. These population-specific differences may be due to different genetic and/or environmental factors contributing to disease pathogenesis.

Twenty-seven of 31 patients were diagnosed with PSP, with recurrent pneumothoraces in 9 patients. Age of onset of pneumothorax recurrence in patients ranged from 15 to 59 years. We calculated the probability of recurrence of PSP in 27 patients based on a generalized
estimate (GEE) in SPSS. The recurrence of PSP was taken as a dependant variable for ‘age of onset of first spontaneous pneumothorax,’ while patient gender, presence/absence of family history, tobacco habits and presence of FLCN pathogenic mutations were considered as cofactors (Additional file 1: Table S15). Analysis revealed a significant association (p-value, 0.047) between the age of onset and PSP recurrence. The mean age of patients with recurrent PSP and single PSP in our cohort are 36 ± 13.01 and 40 ± 11.6 years respectively, with age of onset ≤ 25 years in two recurrent PSP patients. A recent study reported that patients with single PSP are significantly older (mean age: 38.9 ± 16) than patients with recurrent PSP (mean age: 29.7 ± 11) [47]. Therefore, age of onset is an important factor for PSP recurrences in patients.

Genotype-specific phenotypes were not observed in this study. Nineteen BHDS patients with pathogenic FLCN mutations (Table 2), showed lung phenotype with skin fibrofolliculomas in 4 patients and RCC/renal cysts in 2 patients, respectively (Fig. 1). One patient with c.1285delC mutation also presented breast fibroadenoma, which has been reported in another BHDS study with patients negative for pathogenic FLCN mutations [48]. Eleven of 19 patients (57.8%) from 5 families harboured known hotspot mutation—c.1285delC, which was also reported in most of the BHDS patients in other studies. Family based association (using PDT) between BHDS and FLCN mutations has been sparsely done in BHDS studies. Here, we observed that other rare mutation (i.e. novel, hotspot and splice donor mutations) (Table 2), were also significantly associated (Additional file 1: Table S10a) with BHDS in family based study.

Sixteen of 74 asymptomatic members also harbour pathogenic FLCN mutations. Mean age, at onset of BHDS phenotype, of 19 patients with pathogenic FLCN mutations was 44.1 ± 10.9 yrs, which is much higher than the mean age of 16 asymptomatic members (29.5 ± 20.7 yrs) with FLCN mutations. It suggests that, perhaps, a few of the asymptomatic members may manifest BHDS after few years. It may be noted, lower mean age of 16 asymptomatic members may be attributed to the presence of 7 minors (aged ≤ 15 years) in the asymptomatic group. All asymptomatic members also need to be clinically evaluated, since we observed an asymptomatic sibling with c.1285del11 mutation harboring several small basal and bilateral lung cysts after clinical re-evaluation in a previous study [27]. Asymptomatic members with pathogenic mutations may harbour un-ruptured pulmonary cysts and abnormal epithelial/mesenchymal interactions in pleura [49] that may result in PSP later, when combined with other factors.

Homology modelling of interacting proteins with mutant FLCN containing novel and hotspot mutant FLCN significantly affected the protein structures (Fig. 2). Three protein-truncating pathogenic mutations (p.Val384Phefs, p.His429Thrfs and p.Ala445Serfs) were present in C-terminal of FLCN which interacts with FNIP1/2. The stop-gain mutation (p.Gln212Ter) was found in longin domain and it is crucial for Rag-mediated mTORC1 lysosomal activation. Their protein-interacting docking scores also indicated that the FLCN C-terminal mutations substantially reduced the protein stability in the FLCN-FNIP2 complex, while the stop-gain mutation (in longin domain) did so in the 4-protein complex (FLCN-FNIP2-RRAGA-RRAGC).
Large intragenic indels have been reported in BHDS patients [10, 50], however we could not study them using MLPA techniques to detect large intragenic deletion. We addressed the same, using our NGS data and Taqman copy number assay, to check any large FLCN deletion in samples. FLCN targeting NGS data showed a read count difference between patients and asymptomatic members of 4 families (F3, F4, F9 and F10). However, Taqman copy number assays for exons 4, 8 and 13 in FLCN could not detect any significant difference in copy numbers between patients and asymptomatic members. But a significant copy number difference was only observed when Taqman data for exon 8 in patients and asymptomatics were compared with those of unrelated controls (Fig. 3). But we could not validate this difference from NGS data, since we had not taken unrelated controls in the NGS study. Patients from five families (F6, F7, F8, F9 and F10) did not harbour any pathogenic FLCN mutation. This suggests that large deletion mutations at FLCN or mutations in other unknown genes may be associated with disease phenotype. Whole-genome sequencing (WGS) of patients may throw light in these mutations. Our results suggest for copy number differences at exon 8 when compared between BHDS patients and unrelated controls but not at exons 4 and 13, so, more BHDS families may be needed for the study to get real picture of copy number differences. Read count results from targeted amplicon NGS send a cautionary note, as their implied read-count differences between patients and asymptomatic members were not detected in subsequent Taqman assay. Therefore, another validation method is necessary for detection of copy number changes.

PSP or BHDS was not detected in the HPO analysis in patients from family F9 (Additional file 3: Fig. S2), although, the patients were clinically diagnosed as BHDS and have a positive family history of pulmonary cysts. Similarly, two patients from two different families were initially suspected to have LAMS, but genetic evaluation confirmed those as BHDS patients. Therefore, genetic evaluation is necessary for clinically diagnosed BHDS patients.

FLCN Mutations and possible mode of molecular pathogenesis

Four protein truncating mutations (Table 2) were detected in this study and it is reported that misfolded FLCN proteins, due to truncating mutations, may lead to proteosomal degradation. The hotspot mutation, c.1285dupC (H429Pfs), and several C-terminal missense mutations also destabilize the FLCN-FNIP1/2 binding [51]. BHDS patients in our cohort harbour lung cysts, and it was reported that loss of FLCN in murine alveolar cells resulted in dysfunctional activation of AMPK, leading to damaged lung function and apoptotic alveolar cell collapse [15].

Molecular docking analysis revealed that novel stop-gain mutation, p.Gln212Ter affects the FLCN-FNIP2-RRAGA-RRAGC binding and stability. It maps to the longin domain, where another residue, p.Arg164, is reported to be an important catalytic residue for GAP activity in mTORC1 activation in lysosomes [17]. Therefore, functional validation to know the role of the stop-gain mutation in this pathway is required. Three protein-truncating mutations were found in the C terminal region of FLCN, which also directly interacts with Rab7A, involved in lysosomal degradation of epidermal growth factor (EGFR). The study in a BHD-RCC cell line resulted in increased cell proliferation, migration and angiogenesis [20]. Therefore, the C terminal region of FLCN may have important, yet undiscovered, functions that may involve membrane trafficking in BHDS pulmonary phenotype.

Conclusion

This is a first comprehensive genetic study from India with 15 BHDS families (31 patients and 74 asymptomatic individuals). We found 10 of 15 families (66.6%) harbour six pathogenic, protein-truncating FLCN mutations. Among these 6 mutations: two are novel, two were reported Clinvar pathogenic, one was hotspot and the remaining one was reported splice donor mutation. These mutations were significantly associated with disease phenotype in family based PDT study and found in key functional domains that might greatly affect protein binding and downstream signalling pathways. However, we did not find any pathogenic mutations at exons of FLCN in 5 clinically diagnosed BHDS families (F6, F7, F8, F9 and F10). Therefore, we suggest for whole genome sequencing of these patients to detect mutations in exons as well as introns at FLCN and/or other, yet, undescrbed disease genes. Our findings suggest for presence of larger mutational spectrum in Indian patients.

Abbreviations

BHDS: Birt–Hogg–Dubé syndrome; PSP: Primary spontaneous pneumothorax; RCC: Renal cell carcinoma; FLCN: Folliculin; NGS: Next-generation sequencing; FNIP: Folliculin-interacting protein; HPO: Human phenotype ontology; e-QTL: Expression quantitative trait loci; PDT: Pedigree disequilibrium test; RRAG: Ras-related GTP-binding protein.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13023-022-02326-5.

Additional file 1: Supplementary tables
Acknowledgements
Authors would like to thank all patients, their family members, and control healthy individuals for consenting to let their DNA be used in this research. We thank Dr. Ritikha Jha and Dr. Ritabarta Mitra for their clinical insight in the study. Authors are grateful to Mr. Subrata Patra and Mr. Shekhar Ghosh of CoTeRI at NIBMG for their help and support during the NGS experiments. We appreciate and extend heartfelt gratitude to Dr. Analalaha Basu, Dr. Roshni Roy, and Ms. Joyeeta Chakraborty for their valuable suggestions during this study.

Author contributions
BR and AR conceptualized the project, designed the experiments and prepared the manuscript. AR, EC and RC performed the experiments. AR and SG interpreted the data and carried out statistical analysis. AM contributed in targeted NGS experiments. AB, MS, MM, UD, SR, PP, AKP, SRC, NB, RD, ZFU, AD, SM, JMJ referred patients and contributed to clinical diagnosis. BR supervised the study and interpreted the data. All authors read and approved the final manuscript.

Funding
The work was funded by the Indian Statistical Institute, Kolkata, India. Fellowship of A. Ray was funded by CSIR, India. The work was funded by the Indian Statistical Institute, Kolkata, India. Fellowships of A. Ray were funded by CSIR, India.

Availability of data and materials
Additional data are provided in Supplementary materials.

Declarations
Ethics approval and consent to participate
The study was approved by the "Review committee for protection of research risk to humans, Indian Statistical Institute, 2015". Written informed consent from all adult participants and legal guardians/parents for minors were obtained for the research study and subsequent publication of the results. All patient data has been anonymized, and any further information may be obtained from corresponding author.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Human Genetics Unit, Indian Statistical Institute, Kolkata, India. 2. Department of Pulmonary Medicine, RG Kar Medical College and Hospital, Kolkata, India. 3. Respiratory Medicine and Critical Care, Medica Superspeciality Hospital, Guwahati, India. 4. Department of Chest Medicine, Calcutta National Medical College, Kolkata, India. 5. Narayana Superspeciality Hospital, Guwahati, India. 6. Department of Pulmonary Medicine, TMHC and BYL Nar Hospital, Mumbai, India. 7. Department of Chest Medicine, Bombay Hospital Institute of Medical Sciences, Mumbai, India. 8. Ujjwali Hospital and Research Centre, Mumbai, India. 9. Department of Respiratory and Sleep Medicine, Medanta-The Medicity, Gurugram, India. 10. Apollo Hospital Kolkata, Pulmonology, India. 11. Fortis Hospital Kolkata, Pulmonology, India. 12. Department of General Medicine, IPGME&R SSKH Hospital, Kolkata, India. 13. CMRI, C K Birla Group of Hospitals, Kolkata, India. 14. PD. Hinduja Hospital and Research Center, Mumbai, India. 15. National Institute of Biomedical Genomics, Kalyani, India. 16. Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. 17. Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.

Received: 28 January 2022 Accepted: 9 April 2022
Published online: 27 April 2022

References
1. Birt AR, Hogg GR, Dubé WJ. Hereditary Multiple Fibrofolliculomas With Trichodiscomas and Acrochordons. Arch Dermatol. 1977;113:1674.
2. Zbar B, Alvord WG, Glenn G, Turner M, Pavlovich CP, Schmidt L, et al. Risk of renal and congenital neoplasms and spontaneous pneumothorax pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11:393–400.
3. Nickerson ML, Warren MB, Toro JR, Matrosava V, Glenn G, Turner ML, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt–Hogg–Dubé syndrome. Cancer Cell. 2002;2:157–64.
4. Afolabi IZ, Lossos IS, Zlotogora J, Brauer R. On the inheritance of primary spontaneous pneumothorax. Am J Med Genet. 1991;40:155–8.
5. Schmidt LS, Linehan WM. FLCN: the causative gene for Birt–Hogg–Dubé syndrome. Gene. 2018;640:28–42.
6. Kennedy JC, Khabibullin D, Boku Y, Shi W, Henske EP. New developments in the pathogenesis of pulmonary cysts in Birt–Hogg–Dubé syndrome. Semin Respir Crit Care Med. 2020;41:247–55.
7. Schmidt LS, Warren MB, Nickerson ML, Weinrich G, Matrosava V, Toro JR, et al. Birt–Hogg–Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet. 2001;69:876–82.
8. Toro JR, Wei MH, Glenn GM, Weinreich M, Toure O, Vocce K, et al. BHD mutations, clinical and molecular genetic investigations of a Birt–Hogg–Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet. 2008;45:321–31.
9. Vocce CD, Yang Y, Pavlovich CP, Schmidt LS, Nickerson ML, Torres-Cabala CA, et al. High frequency of somatic frameshift BHD gene mutations in Birt–Hogg–Dubé-Associated renal tumors. J Natl Cancer Inst. 2005;97:931–5.
10. Benhammou JN, Vocce CD, Santan A, Schmidt LS, Bamba M, Seyama K, et al. Identification of intragenic deletions and duplication in the FLCN gene in Birt–Hogg–Dubé syndrome. Genes Chromosom Cancer. 2011;50:466–77.
11. Okamoto S, Ebana H, Kunihara M, Mitani K, Kobayashi E, Hayashi T, et al. Folliculin haploinsufficiency causes cellular dysfunction of pleural mesothelial cells. Sci Rep. 2021;11:10814.
12. Nahorski MS, Reiman A, Lim DHK, Nookala RK, Seabra L, Lu X, et al. Birt–Hogg–Dubé syndrome-associated FLCN mutations disrupt protein stability. Hum Mutat. 2011;32:921–9.
13. Chen J, Futami K, Petillo O, Deng J, Wang P, Knol J, et al. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLOS ONE. 2009;4:e5581.
14. Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci USA. 2006;103:15552–7.
15. Goncharova EA, Goncharov DA, James ML, Atochina-Vasserman EN, Stepanova V, Hong SB, et al. Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK. Cell Rep. 2014;7:412–23.
16. Harumi H, Baba M, Hasumi Y, Huang Y, Oh H, Hughes RM, et al. Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN in the pathogenesis of pulmonary cysts in Birt–Hogg–Dubé syndrome. Cancer Cell. 2012;104:1750–64.
17. Shen K, Rogala KB, Chou HT, Huang RK, Yu Z, Sabatini DM. Cryo-EM structure of the human FLCN-FNIP2-Rag-ragulator complex. Cell. 2019;179:1319–29.
18. Nishii T, Tanabe M, Tanaka R, Matsuzawa T, Okuda K, et al. Unique mutation, accelerated mTOR signaling and angiogenesis in the pulmonary cysts of Birt–Hogg–Dubé syndrome. Pathol Int. 2013;63:45–55.
19. Medvetz DA, Khabibullin D, Hariravan H, Ongusaha PP, Goncharova EA, Schlechter T, et al. Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion. PLOS ONE. 2012;7:e47842.
20. Laviolette LA, Mermoud J, Calvo IA, Olson N, Boukhali M, Steinlein OK, et al. Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein. Nat Commun. 2017;8:1–14.
21. Bastola P, Stratton Y, Kellner E, Mikhailova O, Yi Y, Sartor MA, et al. Folliculin contributes to VHL tumor suppressing activity in renal cancer through regulation of autophagy. PLOS ONE. 2013;8:e70030.
22. Lancaster MA, Schroth J, Gleeson JG. Subcellular spatial regulation of canonical Wnt signalling at the primary cilium. Nat Cell Biol. 2011;13:700–7.

23. Laviolette LA, Wilson J, Koller J, Neil C, Hulick P, Rejtar T, et al. Human folliculin delays cell cycle progression through late S and G2/M-phases: effect of phosphorylation and tumor associated mutations. PLOS ONE 2013;8:e66775.

24. Guo T, Shen Q, Ouyang R, Song M, Zong D, Shi Z, et al. The clinical characteristics of East Asian patients with Birt–Hogg–Dubé syndrome. Ann Transl Med. 2020;8:1436. https://doi.org/10.21037/atm-20-1129.

25. Menko FH, van Steensel MA, Giraud S, Friis-Hansen L, Richard S, Ungari et al. Orphanet Journal of Rare Diseases          (2022) 17:176

26. Boone PM, Scott RM, Marciniak SJ, Henske EP, Raby BA. The genetics of pneumothorax. Am J Respir Crit Care Med. 2019;199:1344–57.

27. Ray A, Paul S, Chattopadhyay E, Kundu S, Roy B. Genetic analysis of familial spontaneous pneumothorax in an Indian family. Lung. 2015;193:433–8.

28. Köhler S, Schulz MH, Krawitz P, Bauer S, Dölken S, Ott CE, et al. Clinical diagnostics in human genetics with semantic similarity searches in ontologies. Am J Hum Genet. 2009;85:457–64.

29. Koehler S, Babraham bioinformatics: FastQC, a quality control tool for high throughput sequence data. Soil 1973.

30. Andrews S. Babraham bioinformatics: FastQC, a quality control tool for high throughput sequence data. Soil 1973.

31. Chang X, Wang K. Wannovar: annotating genetic variants for personal genomes via the web. J Med Genet. 2012;49:433–6.

32. Li H, Handsaker B, Wyssokier A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25:2078–9.

33. Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noah K, Kallberg M, et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods. 2018;15:591–4.

34. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22:568–76.

35. Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009;25:1754–60.

36. Poplin R, Ruano-Rubio V, DePristo MA, Fennell TJ, Carneiro MO, Abueva GA Van der, et al. Scaling accurate genetic variant discovery to tens of thousands of samples. BioRxiv. 2017.

37. Kircher M, Witten DM, Jain P, O’roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310–5. https://doi.org/10.1038/ng.2892.

38. Schwarz JM, Cooper DN, Schuelke M, Seelow D. Mutationtaster2: Mutation prediction for the deep-sequencing age. Nat Methods. 2014;11:361–2.

39. Aguet F, Brown AA, Castel SE, Davis JR, He Y, Jo B, et al. Genetic effects on gene expression across human tissues. Nature. 2015;520:204–13.

40. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Afkóldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. bioRxiv. 2020.

41. Wall JD, Stawski EW, Ratan A, Kim HL, Kim C, Gupta R, et al. The Genom-eAsia 100K project enables genetic discoveries across Asia. Nature. 2019;576:106–11. https://doi.org/10.1038/s41586-019-1793-z.

42. Martin ER, Monsks SA, Warren LJ, Kaplan NL. A test for linkage and association in general pedigrees: the pedigree disequilibrium test. Am J Hum Genet. 2000;67:146–54.

43. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26:283–91.

44. Van Zundert GCP, Rodrigues JPGLM, Trellet M, Schmitz C, Kastritis PL, Karaca E, et al. The HADDOCK2.2 web server: user-friendly integrative modeling of biomolecular complexes. J Mol Biol. 2016;428:720–5. https://doi.org/10.1002/jmb.2015.09.014.

45. Fröhlich BA, Zzeit C, Mátyás G, Alkadhri H, Tuor C, Berger W, et al. Novel mutations in the folliculin gene associated with spontaneous pneumothorax. Eur Respir J. 2008;32:1316–20.

46. Castel SE, Cervera A, Mohammad P, Aguet F, Reverter F, Wolman A, et al. Modified penetrance of coding variants by cis-regulatory variation contributes to disease risk. Nat Genet. 2018;50:1327–34. https://doi.org/10.1038/s41588-018-0192-y.

47. Sattler EC, Syunyaeva Z, Mansmann U, Steinlein OK. Genetic risk factors for spontaneous pneumothorax in Birt–Hogg–Dubé syndrome. Chest. 2020;157:1199–206.

48. Khoo SK, Bradley M, Wong FK, Hedblad MA, Nordskjöld M, Teh BT. Birt-Hogg-Dubé syndrome: Mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2. Oncogene. 2001;20:5239–42.

49. Furuya M, Nakatani Y. Birt–Hogg–Dubé syndrome : clinicopathological features of the lung. J Clin Pathol. 2013;66:178–86.

50. Zhang X, Ma D, Zou W, Ding Y, Zhu C, Min H, et al. A rapid NGS strategy for comprehensive molecular diagnosis of Birt–Hogg–Dubé syndrome in patients with primary spontaneous pneumothorax. Respir Res. 2016;17:1–10.

51. Clausen L, Stein A, Granbæk-Thygesen M, Nygaard L, Søltoft CL, Nielsen SY, et al. Folliculin variants linked to Birt-Hogg-Dubé syndrome are targeted for proteasomal degradation. PLOS Genet. 2020;16:e1009187. https://doi.org/10.1371/journal.pgen.1009187.